BioWorld MedTech
Archive Search

User ID


Forgot password

Remember my login

New User ?

BioWorld MedTech Twitter

Clarivate Analytics

Today's Issue of BioWorld MedTech

Friday, May 25, 2018

Featured Headlines

Medtronic adds renal denervation hypertension data as it moves back into pivotal testing

A pivotal clinical trial for renal denervation to treat hypertension is underway on the heels of a pair of recent clinical trial results from Medtronic plc. The company had a phase III failure in this field in 2014, but is convinced that it has altered its approach sufficiently to succeed this time around. The first pivotal trial is in hypertension patients who are not on any medication; potential additional trials in the pivotal program remain under consideration.

CBO sees $1T deficit in 2020 as spending on Medicare spikes

The Congressional Budget Office (CBO) shone a glaring spotlight on the state of the U.S. economy with a report that predicts that the federal budget deficit will reach $1 trillion in 2020 on its way to a deficit of more than $1.5 trillion eight years later. Perhaps even more disturbing for makers of drugs and devices is that Medicare spending has resumed its robust growth rate now that the recession is over, and may double to $1.5 trillion in 2028, roughly the same number as the overall budget deficit in 2028.

Personalized medicine: Some progress but not there yet

CAMBRIDGE, U.K. – "I have trained a large dog to bite anyone who says the words 'personalized medicine.' We are a long way from that." So said George Poste, chief scientist at Complex Adaptive Systems and professor of health innovation at Arizona State University, opening a discussion on the state of play in the field, at the Gap Summit in Cambridge. That is not to say there has been no progress in personalization in the 20 years that Poste has been talking about and been involved in this upcoming new era of medicine.

Home   |   About Us   |   Contact Us   |   Copyright Notices   |   Terms of Use   |   Privacy Statement | |